Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance

被引：16

作者：

Zhang, Haozhe ^{[1
]}

Zhou, Yi ^{[1
]}

Xing, Zengzhen ^{[1
]}

Sah, Rajiv Kumar ^{[1
]}

Hu, Junqi ^{[1
]}

Hu, Hailiang ^{[1
,2
]}

机构：

[1] So Univ Sci & Technol, Sch Med, Dept Biochem, Shenzhen 518055, Peoples R China

[2] Southern Univ Sci & Technol, Key Univ Lab Metab & Hlth Guangdong, Shenzhen 518055, Peoples R China

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 21期

基金：

中国国家自然科学基金;

关键词：

androgen metabolism; androgen receptor; anti-androgen therapy; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; UDP-GLUCURONOSYLTRANSFERASES; INDEPENDENT GROWTH; CYP17A1; INHIBITION; BACKDOOR PATHWAY; RECEPTOR; CASTRATION; TESTOSTERONE; ABIRATERONE; EXPRESSION;

D O I：

10.3390/ijms232113521

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

All aspects of prostate cancer evolution are closely related to androgen levels and the status of the androgen receptor (AR). Almost all treatments target androgen metabolism pathways and AR, from castration-sensitive prostate cancer (CSPC) to castration-resistant prostate cancer (CRPC). Alterations in androgen metabolism and its response are one of the main reasons for prostate cancer drug resistance. In this review, we will introduce androgen metabolism, including how the androgen was synthesized, consumed, and responded to in healthy people and prostate cancer patients, and discuss how these alterations in androgen metabolism contribute to the resistance to anti-androgen therapy.

引用

页数：15

共 50 条

[41] Epigenetic re-programming sensitizes prostate cancer cells to anti-androgen therapy
Xiao, Lanbo
Tien, Jean Ching-Yi
Vo, Josh
Parolia, Abhijit
Wang, Lisha
Tan, Mengyao
Qiao, Yuanyuan
Shukla, Sudhanshu
Wang, Xiaoju
Zheng, Heng
Su, Fengyun
Cao, Xuhong
Chinnaiyan, Arul
CANCER RESEARCH, 2018, 78 (13)
[42] Quantitative proteomic analysis of androgen & anti-androgen responses in the LNCaP prostate cancer cell line
Rowland, JG
Simon, JW
Slabas, AR
Robson, CN
Leung, HY
BRITISH JOURNAL OF CANCER, 2004, 91 : S38 - S38
[43] Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer
Tewari, Alok K.
Cheung, Alexander T. M.
Crowdis, Jett
Conway, Jake R.
Camp, Sabrina Y.
Wankowicz, Stephanie A.
Livitz, Dimitri G.
Park, Jihye
Lis, Rosina T.
Bosma-Moody, Alice
He, Meng Xiao
AlDubayan, Saud H.
Zhang, Zhenwei
McKay, Rana R.
Leshchiner, Ignaty
Brown, Myles
Balk, Steven P.
Getz, Gad
Taplin, Mary-Ellen
Van Allen, Eliezer M.
CELL REPORTS, 2021, 36 (10):
[44] Hormone-refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy
Sciarra, A
Casale, P
Colella, D
Di Chiro, C
Di Silverio, F
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1999, 33 (04): : 211 - 216
[45] Side effects of anti-androgen therapy
Tombal, B.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 : S18 - S18
[46] The effect on prostate volume of anti-androgen versus total androgen blockade in prostate cancer patients - a randomized study
Majumder, K.
Brandberg, Y.
Johansson, H.
Castellanos, E.
Nilsson, S.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S485 - S485
[47] Anti-androgen therapy in triple-negative breast cancer
Barton, Valerie N.
Gordon, Michael A.
Richer, Jennifer K.
Elias, Anthony
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (04) : 305 - 308
[48] Anti-androgen resistance in prostate cancer cells chronically induced by interleukin-1 beta
Staverosky, Julia A.
Zhu, Xin-Hua
Ha, Susan
Logan, Susan K.
AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2013, 1 (01): : 53 - 65
[49] Circumventing anti-androgen resistance by molecular design
McGinley, Paula L.
Koh, John T.
Journal of the American Chemical Society, 2007, 129 (13): : 3822 - 3823
[50] EFFECT OF FLUTAMIDE, AN ANTI-ANDROGEN, ON STAGE-D CANCER OF THE PROSTATE
KASSEM, NY
NERI, RO
MUNROE, JS
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (02) : 256 - 256

← 1 2 3 4 5 →